EUVIMEDEUVIMED entdecken
Multizentrische Studie

Multicenter study to improve clinical interpretation of anticardiolipin and anti-β2-glycoprotein I antibody test results for diagnosis of antiphospholipid syndrome

Lieve Van Hoovels, Silvia Piantoni, Els Bailleul, Sofie Schouwers, Massimo Radin, Maria Infantino, Emirena M Garrafa, Bo Massa, Siska Blomme, Stefanie Van Den Bremt, Bert Vander Cruyssen, Katrien M Devreese und 3 weitere

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2025.05.008 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Lieve Van Hoovels und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, AZORG Hospital Aalst, Aalst, Belgium; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuve…. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, beta 2-Glycoprotein I, Antibodies, Anticardiolipin. Die Arbeit nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Anticardiolipin (aCL) and anti-β2-glycoprotein I (aβ2GPI) antibodies are laboratory markers important for antiphospholipid syndrome (APS) diagnosis and classification. There is an important interassay variation among aCL and aβ2GPI assays. OBJECTIVES: This study aimed to harmonize aCL and aβ2GPI test result interpretation across assays. METHODS: Commercial aCL immunoglobulin (Ig) G/IgM and aβ2GPI IgG/IgM assays from 3 different diagnostic companies (Thermo Fisher Scientific, Orgentec, and Werfen) were evaluated using 176 diagnostic samples from patients with APS and 433 diseased controls. International APS reference materials (Harris/Louisville, Koike/Sapporo, National Institute of Biological Standards and Controls 21/266) were analyzed to evaluate traceability. Reference values were verified using samples from 120 healthy controls. RESULTS: Using the manufacturers' proposed cutoffs, there was large variability in diagnostic sensitivity and specificity among assays. Thresholds corresponding to 97.5% and 99.5% specificity in diseased controls were used to delimit test result intervals (negative [ 99.5% specificity threshold]). Test result interval-specific likelihood ratios (LRs) were concordant across the different aCL and aβ2GPI assays. For all assays, the LR for APS increased with increasing antibody level. Higher LRs were found for IgG than for IgM assays and for double and triple antibody positivity. The added diagnostic value of aβ2GPI IgM was limited. CONCLUSION: Defining thresholds for antibody levels and assigning test result interval-specific LRs allows alignment of clinical interpretation of aCL and aβ2GPI assays.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiphospholipid Syndromebeta 2-Glycoprotein IAntibodies, AnticardiolipinHumansImmunoglobulin MReproducibility of ResultsImmunoglobulin GPredictive Value of TestsFemaleCase-Control StudiesMaleAdultSensitivity and SpecificityBiomarkersMiddle AgedReference Values

Stichwörter der Autor:innen

antiphospholipid antibodiesantiphospholipid syndromeharmonizationlikelihood ratios

Substanzen

beta 2-Glycoprotein IAntibodies, AnticardiolipinImmunoglobulin MImmunoglobulin GBiomarkers

Autor:innen und Institutionen

  • Department of Laboratory Medicine, AZORG Hospital Aalst, Aalst, Belgium; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium. Electronic address: Lieve.Van.Hoovels@azorg.be.
  • Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ERN-Reconnect Member, ASST Spedali Civili and University of Brescia, Brescia, Italy.
  • Department of Laboratory Medicine, AZORG Hospital Aalst, Aalst, Belgium.
  • Department of Laboratory Medicine, ZAS hospitals, Antwerp, Belgium.
  • Center of Research of Immunopathology and Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy, and University of Turin, Torino, Italy.
  • Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Azienda USL-Toscana Centro, Florence, Italy.

Zitieren

APA

Van Hoovels, L., Piantoni, S., Bailleul, E., Schouwers, S., Radin, M., Infantino, M., Garrafa, E. M., Massa, B., Blomme, S., Van Den Bremt, S., Vander Cruyssen, B., Devreese, K. M., Tincani, A., Sciascia, S., & Bossuyt, X. (2025). Multicenter study to improve clinical interpretation of anticardiolipin and anti-β2-glycoprotein I antibody test results for diagnosis of antiphospholipid syndrome. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.05.008

Vancouver

Van Hoovels L, Piantoni S, Bailleul E, Schouwers S, Radin M, Infantino M, et al. Multicenter study to improve clinical interpretation of anticardiolipin and anti-β2-glycoprotein I antibody test results for diagnosis of antiphospholipid syndrome. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.05.008

BibTeX
@article{VanHoovels2025,
  author = {Van Hoovels, Lieve and Piantoni, Silvia and Bailleul, Els and Schouwers, Sofie and Radin, Massimo and Infantino, Maria and Garrafa, Emirena M and Massa, Bo and Blomme, Siska and Van Den Bremt, Stefanie and Vander Cruyssen, Bert and Devreese, Katrien M and Tincani, Angela and Sciascia, Savino and Bossuyt, Xavier},
  title = {Multicenter study to improve clinical interpretation of anticardiolipin and anti-β2-glycoprotein I antibody test results for diagnosis of antiphospholipid syndrome},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2025.05.008}
}
Kostenlos starten →